Objective: To analyze the serotype distribution and drug resistance of Streptococcus pneumoniae isolated from pediatric patients in a Chinese hospital.
resistant to cephalosporin, macrolides, tetracycline (TET), and sulfonamide antibiotics. Managing pediatric pneumococcal infection has become a huge challenge due to drug resistance and to the pathogenic mechanism; strategies to circumvent these issues have gradually become the focus of attention among researchers. 7 In this study, we quantified the serotype and drug resistance of isolates from pediatric patients at Wenling Maternal and Child Health Care Hospital who harbored pneumococcal species and we investigated the coverage rate of PCV7, PCV10, and PCV13, to provide relevant information to guide clinical treatment.
Materials and Methods

Resources Used in Isolating Strains
From October 10, 2011, to May 23, 2014, we collected a total of 284 isolates from pediatric patients at Wenling Maternal and Child Health Care Hospital. In these isolates, there were 217 noninvasive strains, which included 169 strains from qualifying sputum (leukocytes >25/low power field [LPF] , epithelia <10/LPF) and 48 strains from bronchoalveolar lavage fluid. In 67 invasive strains, 4 were from cerebrospinal fluid (CSF) and 2 from blood; the others were from pleural effusions and ascites. When strains were collected at different times or from different places but belonged to the same patient, we studied only 1 strain, with preferential choice of invasive or first-isolated strain. The protocols were approved by the Ethics Committee of Wenling Maternal and Child Health Care Hospital, and informed written consent was obtained from participants before they participated in this study.
Equipment and Reagents
We used Epsilomer test (E-test) drug sensitivity test strips, including amoxicillin (AMX)/clavulanic acid (CLA), cefatriaxone (CRO), erythromycin (ERY), and vancomycin (VAN). The Kirby-Bauer (K-B) disk susceptibility method was used for testing the sensitivities of various drugs, including penicillin (PEN), chlorampheniccol (CHL), erythromycin (ERY), trimethoprim-sulfamethoxazole (SXT), levofloxacin (LEV), tetracycline (TET), clindamycin (CLI), and rifampicin (RFP). We also used a VITEK-32 instrument for microbial identification and susceptibility analyzing (bioMé rieux SA). Omni S. pneumoniae total serum and serotyping serum were from the Statens Serum Institute. S. pneumoniae ATCC 49619, from the American type culture collection (ATCC), was used as the control organism for E-test and disk diffusion testing.
Strain Identification
We inoculated the specimens onto agar plates containing 5% sheep blood and incubated them at 37 C in a 5% CO 2 atmosphere for 24 hours. We collected suspected colonies with alpha hemolysis that had a concave shape and had arisen in umbilical cord blood. We further detected such colonies using the optochin sensitivity test, the bile solubility test, and Omni S. pneumoniae total serum. 8 All of these isolates were stored at À80 C in frozen tubes containing equine serum.
Serotyping
The isolates were serotyped with Quellung reactions (biochemical reactions in which antibodies bind to the bacterial capsule of S. pneumonia and certain other bacteria; the antibody reactions allow these species to be visualized under a microscope 
Statistical Analysis
We analyzed the antimicrobial susceptibility data that we had gathered, using WHONET 5.6 software. The statistical significance of data was tested using Statistical Package for Social Science (SPSS) software for Windows, version 17.0 (SPSS Inc.), in which the v 2 test or Fisher exact test was used. A 2-tailed cutoff of P <.05 was considered to be statistically significant.
Results
General Information about Pediatric Patients
Among the 284 total pediatric patients infected with S. pneumoniae, 193 were boys and 91 were girls, aged 0 to 107 months, with a median age of 15 months. Most patients (81.4%) were younger than 3 years old: 126 patients (44.4%) were younger than 12 months, 103 patients (36.3%) were aged between 12 months and 36 months, 37 patients (13.0%) were aged between 36 months and 60 months (13.0%), and 18 patients (6.3%) were older than 60 months.
Serotype Distribution of S. pneumoniae
We identified 17 serotypes in the 284 isolates. In 217 noninvasive strains, 210 strains were serotyped using the We isolated from CSF 1 invasive strain that could not be serotyped with the serums used in this study. The serotypes of these S. pneumoniae isolated from clinical patients are listed in Table 2 .
The distributions of the same serotype from different strains had no statistically significant difference. In 284 isolates, the coverage rates of PCV7, PCV10, and PCV13 were 58.8% (117/217), 58.1% (165/284), and 85.2% (242/284), respectively. In 217 noninvasive strains, the coverage rates of PCV7 and PCV10 were 53.9% (117/217); this rate for PCV13 was 86.2% (187/217), which was significantly higher than that of PCV7 (v 2 ¼19.8; P <0.01) and PCV10
(v 2 ¼19.7;P <0.01). In the 67 invasive strains, the coverage rates for PCV7, PCV10, and PCV13 were 77.6% (52/67), 82.1% (55/67), and 91.0% (61/67), respectively. The v 2 value was 0.667 between PCV7 and PCV13, with P > .05. The results showed no statistical differences in coverage rates for the 3 vaccines regarding invasive strains.
Antibiotics Susceptibility Test
The results for sensitivities of 284 isolates to 11 antibiotics are listed in Table 3 and Table 4 . For nonmeningitis isolates, the sensitivity rate to PEN was 95.0%; however, but the susceptible rate to CRO was only 79%. Two strains, isolated from meningitis and marked as undifferentiated type, showed resistance to PEN, ERY, SXT, CLI, and TET; showed intermediate resistance to CRO; and showed sensitivity to AMX/CLA, VAN, LEV, and RFP. All of these strains were resistant to ERY and had minimum inhibitory concentrations (MICs) of 99%, or greater than 256 mg per L.
The resistant rates of all the isolates to SXT, TET, and CLI were 84.5%, 85.9%, and 97.8%, respectively. All of the specimens were sensitive to VAN, LEV, and RFP. The rate of multidrug resistance among 284 isolates was 98.2% (279/284). The most common pattern of multidrug 
Detection of the Drug Resistance Gene in Macrolides
In this study, the MICs of ERY in all isolates were greater than 256 mg per L with 1 exception, for which the MIC was Table 5 .
Discussion
The serotypes of S. pneumoniae varied along with the different isolation sources and regions. In this report, the most common serotypes of noninvasive strains were 19F, 19A, 23F, and 6A. The top 4 serotypes, isolated from respiratory specimens of pediatric patients infected with pneumococci in 5 children's hospital in mainland China, were reported in 2011 as 19F, 19A, 23F, and 6B; the 3 most common of those were 19F, 19A, and 23F, 11 as in our results.
The most common serotypes of noninvasive pneumococcal strains from the upper respiratory tracts of children were 6B, 19F, 23F, and 6C. 12 Those findings suggests that the major serotypes of the upper and lower respiratory tracts are different. In our research, the most common serotypes of invasive strains were 23F, 14, 6B, and 19A. In a 2013 survey of serotypes of invasive strains isolated from pediatric pneumococcal patients in Shenzhen, China, 19F, 14, 23F, 19A, and 6B were the most common serotypes. 9 The prevalence of these reported serotypes was similar to that found in our results; however, the distribution pattern and rates differed. According to a report of the serotypes of 386 invasive pneumococcal strains collected from 8 hospitals and institutes from 1996 through 2008 in South Korea, the 5 most common were 19F, 23F, 19A, 6A, and 3.
10
The first vaccine used for prevention of pediatric pneumococcal infection was PCV7. Since 2000, when United States physicians began to use PCV7 in American health care facilities, the incidence rates of meningitis, pneumonia, and septicemia have been significantly reduced. According to a research study conducted in California, from 2000 through 2005, the incidence rate of invasive pneumococcal infection in children younger than 5 years declined from 62.5 per 100,000 individuals per year to 15.3 per 100,000 individuals per year, and the rate of invasive pneumococcal diseases caused by serotypes targeted by PCV7 was reduced by 90%.
11
However, diseases caused by serotypes unrelated to vaccines occurred more frequently: serotypes 1, 3, 6A, 7F, and 19A have become the main causative pathogens in some European countries. 12 PCV10 and PCV 13 target more serotypes than PCV7 and thus have replaced PCV7 in general use. An estimation of the immune-system effect of PCV10 showed that the incidence rate of invasive pneumococcal infection of children between the ages of 0 and 2 years was reduced from 16.47 per 1,000 to 0.44 per 1,000, and the rate of decline was 89%. 13 These results also showed that PCV13, the serotype targeting range of which included 19A, yielded strong preventative effects against pneumococcal infection, especially against mastoiditis.
14 According to our research, the coverage rate of PCV13 detected from noninvasive strains was 31.7% greater than that of PCV7 and PCV10. In invasive stains, the coverage rate of PCV13 was increased 14.4% compared with that of PCV7 and was increased 9.5% compared with PCV10.
Comparing the serotype distribution of noninvasive and invasive pneumococcal strains, we noticed clearly that 19A was targeted by PCV13, which provided the main explanation of why PCV13 had a higher coverage rate, as also observed in the results of a previous report. 15 For many years, PEN was the standard treatment of pediatric pneumococcal infection. However, the increased resistance of many bacterial strains to PEN has challenged the accepted clinical treatment of this disease. Since 2008, the requirement of PEN-resistant pneumococcal strains isolated from non-CSF specimens has been revised by CLSI. The previous standard was sensitivity of 0.06 mL per L or less and resistance of 2 mg per L or greater, whereas the revised standard was sensitivity of 2 mg per L or less and resistance of 8 mg per L or greater. This revised standard helped to significantly reduce the rate of PEN resistance.
In the results of this study, the results of MIC50 (the lowest concentration of the antibiotic at which 50% of the isolates are inhibited) testing of non-CSF strains to PEN was 1 mg per L. This value is greater than the value of 0.032 mg per L to 0.25 mg per L that was reported in a previous research work. 16 Our isolates had resistance of 0 to VAN, LEV, and RFP. The resistance of pediatric pneumococci isolates in the Asian region to macrolides showed a higher tendency toward drug resistance, 17 which we could not ignore. There were 2 main mechanisms of resistance to macrolides in pneumococci. The first one was the change of target site caused by the ribosomal methylation enzyme encoded by the ermB gene, which methylated the single adenines of 23s ribosomal RNA (rRNA) to reduce the affinity between macrolides and the target site of the ribosome in question. The other mechanism was the active efflux system, through which antibiotics were pumped out of the cell by proteins coded by the mef gene. 18, 19 The resistance of 284 isolates to ERY was 100%; also, 38.4% of these specimens contained the mefA gene, and all of the specimens contained ermB. In the 284 isolates, strains containing the highest proportion of mefA gene were 19F and 19A. These 2 strains have been reported 20 to have higher rates of mefA than other serotypes.
It was assumed that, under the screening pressures of antibiotics, 19F and 19A probably had cloning transmission.
We detected and analyzed the serotypes and drug resistance of 284 isolates from clinical pediatric patients with pneumococcal infection; 17 serotypes were identified, the most common of which were 19F, 19A, 23F, 6A, and 14.
Compared with PCV and PCV10, PCV13 targeted 19A, which had a higher rate of isolation and drug resistance than other isolates. PCV13 played a more prominent role in prevention of pneumococcal diseases and control of multidrug resistance than other PCV variants. The rate of PEN susceptibility in nonmeningitis strains was 95.0%. All of the specimens were resistant to ERY and contained the ermB gene; 38.4% also contained the mefA gene.
Considering the limited number of total strains and invasive strains we examined in our research, more data are still needed, in a longer period, to verify further our results. The change of serotypes and drug resistance should be dynamically monitored so that more useful information can be supplied for prevention and treatment of pneumococcal infection. LM
